Expression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma

Diagnostic Pathology

Weiping Zheng²  Zhenniu Lei⁴  Bin Shen⁴  Shengjing Liang⁴  Jiao Lan¹  Baijun Li⁴  Hui Lin⁴  Lingyu Jiang³  Yonglong Zhong⁴ 

[1] Research Center of Medical Sciences, the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, P.R. China;Provincial Clinical Medical College of Fujian Medical University, Fuzhou 350000, P.R. China;Intensive Care Unit, the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, P.R. China;Department of Thoracic Cardiovascular Surgery, the People’s Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning 530021, P.R. China

关键词: Immunohistochemistry;    Lung adenocarcinoma;    Prognosis;    Lymph node metastasis;    Aggressive behavior;    Chemokine receptor 9;   

Others  :  1219338
DOI  :  10.1186/s13000-015-0341-x

 received in 2015-05-14, accepted in 2015-06-29,  发布年份 2015

【 摘 要 】

Background

The CC chemokine receptor 9 (CCR9) plays an important role in tumorigenesis and metastasis in various cancers. Our previous studies have shown the aberrant expression of CCR9 in non-small cell lung cancer (NSCLC) cell lines, revealing that the CCR9-CCL25 axis modulates cell migration and invasion, and supports cancer cell survival by inhibiting apoptosis in vitro and in vivo. In the present study, we aimed to evaluate the expression and possible prognostic role of CCR9 in lung adenocarcinoma.

Methods

Immunohistochemical analysis of CCR9 expression was performed on 144 lung adenocarcinoma tissues and 30 adjacent normal lung parenchymal tissues. We assessed the correlation of CCR9 expression with clinicopathological characteristics and the prognosis of lung adenocarcinoma.

Results

The expression of CCR9 was increased in lung adenocarcinoma tissue compared with normal lung tissue. Moreover, such an expression was positively correlated with tumor size (p = 0.032), lymph node metastasis (p = 0.002) and advanced TNM stage (p = 0.012). In addition, the patients with negative CCR9 expression exhibited a higher overall survival (OS) compared with those with positive CCR9 expression. Multivariate analysis showed that the CCR9 expression was an independent prognostic factor for the OS of patients with lung adenocarcinoma.

Conclusions

We, for the first time, reported that CCR9 could be beneficial in predicting lymph node metastasis, and it might act as a novel prognostic biomarker for lung adenocarcinoma.

【 授权许可】

   
2015 Zhong et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014; 64:9-29.
• [2]DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. CA: A Cancer Journal for Clinicians. 2014; 64:252-71.
• [3]Balkwill FR. The chemokine system and cancer. J Pathol. 2012; 226:148-57.
• [4]Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010; 21:27-39.
• [5]Mukaida N, Sasaki S, Baba T. Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm. 2014; 2014:170381.
• [6]Vela M, Aris M, Llorente M, Garcia-Sanz JA, Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol. 2015; 6:12.
• [7]Youn BS, Kim CH, Smith FO, Broxmeyer HE. TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6/CCR9 as a specific receptor. Blood. 1999; 94:2533-6.
• [8]Uehara S, Grinberg A, Farber JM, Love PE. A role for CCR9 in T lymphocyte development and migration. J Immunol. 2002; 168:2811-9.
• [9]Zhang Z, Qin C, Wu Y, Su Z, Xian G, Hu B. CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma. Oncol Rep. 2014; 31:1629-36.
• [10]Fan J, Zhang L, Wang QL, Lin H. Chemokine receptor 9 high-expression involved in the migration and invasion of the non-small-cell lung cancer cells. Asian Biomedicine. 2011; 5:45-52.
• [11]Li B, Wang Z, Zhong Y, Lan J, Li X, Lin H. CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway. Med Oncol. 2015; 32:66.
• [12]Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN et al.. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50-6.
• [13]Itakura M, Terashima Y, Shingyoji M, Yokoi S, Ohira M, Kageyama H, Matui Y, Yoshida Y, Ashinuma H, Moriya Y et al.. High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. Br J Cancer. 2013; 109:1100-8.
• [14]Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT et al.. Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer. 2015; 15:441. BioMed Central Full Text
• [15]Svensson M, Agace WW. Role of CCL25/CCR9 in immune homeostasis and disease. Expert Rev Clin Immunol. 2006; 2:759-73.
• [16]Qiuping Z, Qun L, Chunsong H, Xiaolian Z, Baojun H, Mingzhen Y, Chengming L, Jinshen H, Qingping G, Kejian Z et al.. Selectively increased expression and functions of chemokine receptor CCR9 on CD4+ T cells from patients with T-cell lineage acute lymphocytic leukemia. Cancer Res. 2003; 63:6469-77.
• [17]Letsch A, Keilholz U, Schadendorf D, Assfalg G, Asemissen AM, Thiel E, Scheibenbogen C. Functional CCR9 expression is associated with small intestinal metastasis. J Invest Dermatol. 2004; 122:685-90.
• [18]Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JJ. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004; 10:8743-50.
• [19]Shen X, Mailey B, Ellenhorn JD, Chu PG, Lowy AM, Kim J. CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg. 2009; 13:1955-62.
• [20]Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res. 2009; 15:2962-70.
• [21]Johnson EL, Singh R, Singh S, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JJ. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol. 2010; 8:62. BioMed Central Full Text
• [22]Chen HJ, Edwards R, Tucci S, Bu P, Milsom J, Lee S, Edelmann W, Gumus ZH, Shen X, Lipkin S. Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. J Clin Invest. 2012; 122:3184-96.
• [23]Johnson-Holiday C, Singh R, Johnson E, Singh S, Stockard CR, Grizzle WE, Lillard JJ. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int J Oncol. 2011; 38:1279-85.
• [24]Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek EJ. The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol. 2012; 4:128-34.
• [25]Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012; 13:287-97.
• [26]Gupta P, Sharma PK, Mir H, Singh R, Singh N, Kloecker GH, Lillard JJ, Singh S. CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis. Oncotarget. 2014; 5:10170-9.
• [27]Li J, Li Q. The expression of CCL25/CCR9 in pancreatic cancer. Chin J Hepatobiliary Surg. 2011; 17:475-8.
• [28]Johnson EL, Singh R, Johnson-Holiday CM, Grizzle WE, Partridge EE, Lillard JJ, Singh S. CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res. 2010; 3:15. BioMed Central Full Text
• [29]Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JJ, Singh S. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol. 2011; 9:46. BioMed Central Full Text